Neurofibrillary Tangle Formation
Amyloid plaques, neurofibrillary tangles (NFTs), and neuronal loss are the major pathological hallmarks of Alzheimer’s disease (AD). NFTs are intracellular aggregates of hyperphosphorylated Tau. Tau is a highly soluble, unfolded microtubule-associated protein (MAP) that regulates microtubule dynamics and reorganization. It is abundant in the central nervous system, specifically in the axons of mature neurons, where it regulates axon elongation, maturation, and transport.
Tau is a phosphoprotein that, under physiological conditions, has about 30 of its available 79 Ser and Thr phosphorylation sites phosphorylated. A multitude of kinases phosphorylate Tau including GSK-3 beta, CDK5, and PKA. On the other hand, only a small number of phosphatases, such as PP2A and Calcineurin A, dephosphorylate Tau. In AD and other tauopathies, Tau becomes hyperphosphorylated; however, the causes leading to abnormal Tau hyperphosphorylation are still not fully understood.
Hyperphosphorylated Tau is thought to exert its pathological effects by several mechanisms. As previously stated, hyperphosphorylation of Tau causes it to transform into PHF-Tau (paired helical filament) and NFTs. Phosphorylated Tau also detaches from microtubules and is aberrantly trafficked from axons to the cell body and dendrites, where is aggregates and interferes with normal synaptic transmission. Additionally, hyperphosphorylated Tau impairs proteosomal degradation and autophagy, thereby inhibiting Tau turnover. R&D Systems offers a range of research tools for investigating Tau phosphorylation and NFT formation.
-
Microtubules, MAPs, and Related Products
-
Tau Kinases and Related Products
- Akt (Protein Kinase B) Activators
- Akt (Protein Kinase B) Inhibitors
- Akt1
- Akt2
- Akt3
- AMPK Activators
- AMPK alpha 1
- AMPK alpha 2
- AMPK beta 1
- AMPK beta 2
- AMPK gamma 1
- AMPK gamma 3
- AMPK Inhibitors
- CaM Kinase II
- CaM Kinase II alpha
- CaM Kinase II delta
- CaM Kinase II gamma
- CaM Kinase Inhibitors
- Casein Kinase 1 delta
- Casein Kinase 1 Inhibitors
- CDC2/CDK1
- CDK2
- CDK5
- Checkpoint Kinase Inhibitors
- Chk2
- Cyclin-dependent Kinase Inhibitors
- DDR2
- DYRK Inhibitors
- DYRK1A
- ERK1/ERK2
- ERK1
- ERK2
- Fyn
- Glycogen Synthase Kinase Inhibitors
- GSK-3 alpha/beta
- GSK-3 alpha
- GSK-3 beta
- GSK-3 Inhibitors
- JNK
- JNK1/JNK2
- JNK/c-jun Activators
- JNK/c-jun Inhibitors
- JNK1
- JNK2
- JNK3
- Lck
- MELK
- MKK3
- p38
- p38 alpha
- p38 gamma
- p38 delta
- p38 Inhibitors
- PKA C (pan)
- PKA C alpha
- PKA C alpha/beta
- PKA C beta
- PKA RI beta
- PKA RII alpha
- PKC delta
- Protein Kinase A Activators
- Protein Kinase A Inhibitors
- Protein Kinase A Modulators
- Protein Kinase C Activators
- Protein Kinase C Inhibitors
- Src Family Kinase Activators
- Src Family Kinase Inhibitors
-
Tau Phosphatases and Related Products
-
Tau-Binding Proteins and Related Products
- 14-3-3
- 14-3-3 beta
- 14-3-3 gamma
- 14-3-3 epsilon
- 14-3-3 eta
- 14-3-3 sigma
- 14-3-3 theta
- 14-3-3 zeta
- 14-3-3 Inhibitors
- Actin
- Actin-related Products
- Annexin A2
- Apolipoprotein E/ApoE
- Bag-1
- Calmodulin 1
- DNAH17
- Dynactin Subunit 1/DCTN1
- Dynactin Subunit 2/DCTN2
- Fgr
- FKBP51
- FKBP52
- Fyn
- GRB2
- HSP27
- HSP70/HSPA1A
- HSP70 Inhibitors
- HSP70 Modulators
- HSP90
- HSP90 alpha
- HSP90 beta
- HSP90 Inhibitors
- JIP1
- Lck
- NF-H
- NF-L
- NF-M
- PI 3-Kinase p85 alpha
- Pin1
- PLC-gamma 1
- Presenilin-1
- S100B
- Sirtuin 1/SIRT1
- Src
- Src Family Kinase Activators
- Src Family Kinase Inhibitors
- alpha-Synuclein
- Ubiquitin
-
Tau-Cleaving Enzymes and Related Products